| Literature DB >> 23844109 |
Jean-Philippe Lavigne1, Gaelle Cuzon, Christophe Combescure, Gisèle Bourg, Albert Sotto, Patrice Nordmann.
Abstract
Klebsiella pneumoniae carbapenemase (KPC) is a carbapenemase increasingly reported worldwide in Enterobacteriaceae. The aim of this study was to analyze the virulence of several KPC-2-producing K. pneumoniae isolates. The studied strains were (i) five KPC-2 clinical strains from different geographical origins, belonging to different ST-types and possessing plasmids of different incompatibility groups; (ii) seven transformants obtained after electroporation of either these natural KPC plasmids or a recombinant plasmid harboring only the bla KPC-2 gene into reference strains K. pneumoniae ATCC10031/CIP53153; and (iii) five clinical strains cured of plasmids. The virulence of K. pneumoniae isolates was evaluated in the Caenorhabditis elegans model. The clinical KPC producers and transformants were significantly less virulent (LT50: 5.5 days) than K. pneumoniae reference strain (LT50: 4.3 days) (p<0.01). However, the worldwide spread KPC-2 positive K. pneumoniae ST258 strains and reference strains containing plasmids extracted from K. pneumoniae ST258 strains had a higher virulence than KPC-2 strains belonging to other ST types (LT50: 5 days vs. 6 days, p<0.01). The increased virulence observed in cured strains confirmed this trend. The bla KPC-2 gene itself was not associated to increased virulence.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23844109 PMCID: PMC3699468 DOI: 10.1371/journal.pone.0067847
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Main characteristics of the strains and plasmids used in this study.
| Strain or plasmid | Source | Plasmid gene contents | ST | Virulence traits | Reference |
|
| FDA | – | – |
| ATCC collection |
|
| Clinical (Colombia) |
| 337 |
| 7 |
|
| Clinical (Colombia) |
| 338 |
| 7 |
|
| Clinical (USA) |
| 258 |
| 8 |
|
| Clinical (Brazil) |
| 11 |
| 9 |
|
| Clinical (Israel) |
| 277 |
| 10 |
| CIP53153+ pBC2303 | Transformant with plasmid extracted from KN2303 |
| – | – | This study |
| CIP53153+ pBC633 | Transformant with plasmid extracted from KN633 |
| – | – | This study |
| CIP53153+ pNYC | Transformant with plasmid extracted from YC |
| – | – | This study |
| CIP53153+ pA28006 | Transformant with plasmid extracted from A28006 |
| – | – | This study |
| CIP53153+ p475 | Transformant with plasmid extracted from 475 |
| – | – | This study |
| CIP53153+ pBKCMV | Transformant with a plasmid wich was used for the cloning experiment | – | – | – | This study |
| CIP53153+ pRYC-1 | Transformant with a plasmid containing the |
| – | – | This study |
| KN2303– pBC2303 | Plasmid cure derivative strain | – | 337 | – | This study |
| KN633– pBC633 | Plasmid cure derivative strain | – | 338 | – | This study |
| YC – pNYC | Plasmid cure derivative strain | – | 258 | – | This study |
| A28006– pA28006 | Plasmid cure derivative strain | – | 11 | – | This study |
| 475– p475 | Plasmid cure derivative strain | – | 277 | – | This study |
| pBKCMV | Vector | – | – | 11 | |
| pRYC-1 | pBKCMV-derivated recombinant plasmid carrying |
| – | – | 11 |
Antibiotic susceptibility of the K. pneumoniae transformant strains.
| MIC (µg/ml) | ||||||
| Antibiotics |
|
|
|
|
|
|
| Amoxicillin | 96 | ≥256 | ≥256 | ≥256 | ≥256 | ≥256 |
| Amoxicillin+CLA | 2 | ≥256 | ≥256 | ≥256 | ≥256 | ≥256 |
| Ticarcillin | 96 | ≥256 | ≥256 | ≥256 | ≥256 | ≥256 |
| Ticarcillin+CLA | 1.5 | ≥256 | ≥256 | ≥256 | ≥256 | ≥256 |
| Piperacillin | 2 | ≥256 | ≥256 | ≥256 | ≥256 | ≥256 |
| Piperacillin+TZB | 0.094 | ≥256 | ≥256 | ≥256 | ≥256 | ≥256 |
| Ceftazidime | 0.094 | 12 | 16 | 24 | 32 | 16 |
| Imipenem | 0.19 | 8 | 8 | 12 | 8 | 8 |
| Ertapenem | 0.016 | 4 | 3 | 4 | 4 | 4 |
| Tigecycline | 0.125 | 0.125 | 0.125 | 0.125 | 0.125 | 0.125 |
| Gentamicine | <2 | <2 | <2 | >4 | <2 | <2 |
| Tobramycin | <2 | <2 | <2 | >4 | <2 | <2 |
| Amikacin | <2 | <2 | <2 | <2 | <2 | <2 |
| Ciprofloxacin | <0.5 | <0.5 | <0.5 | <0.5 | <0.5 | <0.5 |
| Cotrimoxazole | <1 | <1 | <1 | >4 | <1 | <1 |
| Colistin | <2 | <2 | <2 | <2 | <2 | <2 |
Letal Time 50% (LT50) of Caenorhabditis elegans infected by clinical and transformant K. pneumoniae strains.
| StrainCharacteristics of strain | LT50 in days | (Mean ±se) |
| ||||
| ATCCvs other strains | clinical vs transformants/derivatives | 475,YC,A28006 (clinical/mutants)vs 2303,633 (clinical/mutants) | pRYC-1 vs other strain | ||||
| ATCC10031/CIP53153 | Reference | 4.3±0.2 | – | NS | |||
| KN2303 | Clinical isolate | 5.7±0.3 | <0.001 | NS | <0.01 | <0.001 | |
| KN633 | Clinical isolate | 6.0±0.5 | <0.001 | NS | <0.01 | <0.001 | |
| YC | Clinical isolate | 5.3±0.2 | <0.001 | NS | <0.01 | <0.001 | |
| A28006 | Clinical isolate | 5.0±0.5 | <0.001 | NS | <0.01 | <0.001 | |
| 475 | Clinical isolate | 5.3±0.2 | <0.001 | NS | <0.01 | <0.001 | |
| CIP53153+ pBC2303 | Transformant | 5.9±0.1 | <0.001 | NS | <0.01 | <0.001 | |
| CIP53153+ pBC633 | Transformant | 6.3±0.2 | <0.001 | NS | <0.01 | NS | |
| CIP53153+ pNYC | Transformant | 5.6±0.4 | <0.001 | NS | <0.01 | <0.001 | |
| CIP53153+ pA28006 | Transformant | 5.5±0.5 | <0.001 | NS | <0.01 | <0.001 | |
| CIP53153+ p475 | Transformant | 5.5±0.5 | <0.001 | NS | <0.01 | <0.001 | |
| pBk-CMV | Transformant | 4.6±0.3 | NS | – | – | – | |
| pRYC-1 | Transformant | 6.6±0.4 | <0.001 | – | – | <0.001 | |
| KN2303– pBC2303 | Plasmid cured derivative | 5.0±0.5 | <0.001 | <0.001 | <0.01 | <0.01 | |
| KN633– pBC633 | Plasmid cured derivative | 5.0±0.5 | <0.001 | <0.001 | <0.01 | <0.01 | |
| YC – pNYC | Plasmid cured derivative | 4.7±0.3 | NS | <0.001 | <0.01 | <0.01 | |
| A28006– pA28006 | Plasmid cured derivative | 4.3±0.3 | NS | <0.001 | <0.01 | <0.01 | |
| 475– p475 | Plasmid cured derivative | 4.5±0.5 | NS | <0.001 | <0.01 | <0.01 | |
| OP50 | Avirulent, nematode food | 8.2±0.3 | <0.001 | – | – | – | |
LT50 corresponds to the time for half of the worms to die. The results are representative of at least five independent trials for each group of strains.
Lawn-leaving behavior of the different strains.
| Strains | % occupancy after 16 h | |
|
|
| 100 (±1) |
|
|
| 98 (±2) |
|
| 97 (±3) | |
|
| 100 (±1) | |
|
| 99 (±1) | |
|
| 100 (±1) | |
|
| pBC2303 | 99 (±2) |
| pBC633 | 97 (±4) | |
| pNYC | 99 (±2) | |
| pA28006 | 100 (±1) | |
| p475 | 100 (±1) | |
| pBk-CMV | 97 (±2) | |
| pRYC-1 | 100 (±1) | |
|
| KN2303– pBC2303 | 100 (±1) |
| KN633– pBC633 | 98 (±2) | |
| YC – pNYC | 98 (±2) | |
| A28006– pA28006 | 100 (±1) | |
| 475– p475 | 100 (±2) | |